Avaxia is developing oral antibody products for diseases and disease targets that can be reached through the mouth and the gastrointestinal tract.

Our products are bovine polyclonal antibodies, isolated from the early milk of immunized cows. Nature has designed these antibodies to be both stable to gastric digestion and safe for oral consumption.

We have built a proprietary technology platform on this natural source of antibodies. Our platform offers unique advantages in product safety, cost and convenience. Just as importantly, we offer more rapid clinical development at a greatly reduced cost.

Avaxia is using our platform technology to develop medication to treat serious diseases, many of them currently untreated by existing technologies.


Date Type Amount Investors Valuation
11/01/11 Series A 2.2M Cherrystone Angels, Boston Harbor Angels Unknown